uMotif

About uMotif

uMotif is a London-based digital health company that offers a patient-centric data capture platform for clinical research. Founded in 2012 by Bruce Hellman and Ben James, the company's mission is to place patients at the heart of clinical studies. The idea was sparked after the co-founders met with two Parkinson's Disease patients who wanted digital tools to better track and understand their condition and healthcare journey. Co-founder Bruce Hellman has a background in clinical trials and an MBA from Imperial College, which provided a strong foundation in business and the importance of user-centric design.

The company provides a software-as-a-service (SaaS) application that enables patients to track their health and self-reported outcomes through a mobile app. This cloud-native platform is designed for pharmaceutical companies, biotechs, contract research organizations (CROs), and academic institutions. It captures regulatory-compliant data such as eConsent, electronic Clinical Outcome Assessments (eCOA), and Patient-Reported Outcomes (ePRO), as well as data from wearable devices. The business model serves clients like AstraZeneca, Abbvie, and Syneos, helping them achieve high rates of data capture (in excess of 90%), improve patient retention, and accelerate research timelines. By focusing on a user-friendly experience, the platform aims to reduce the burden on study participants, leading to higher compliance and data quality.

uMotif's platform supports various study designs, from traditional site-based trials to fully decentralized and post-marketing research. Its solutions include Trial Awareness and Patient Ride with Uber Health to bolster the patient-site relationship. The company has raised a total of $35.4 million over six funding rounds, with its latest Series B round in May 2022 securing $25.5 million, led by Athyrium Capital Management. This funding supports international expansion, particularly in North America, and further platform development.